Biocryst Press Release. on MarketScreener. BioCryst leverages its expertise in struct
on MarketScreener. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat RESEARCH TRIANGLE PARK, N. , Dec. BioCryst Pharmaceuticals (NASDAQ:BCRX) on Friday announced an agreement to sell European business related to its bestselling therapy Orladeyo to Neopharmed Gentili, an Italian View the latest Biocryst Pharmaceuticals (BCRX) company-issued press releases. , May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first Company Profile BioCryst Pharmaceuticals, Inc. Forward-Looking Statements This press release contains forward-looking statements, For more information, please visit www. 12, 2025 Forward-Looking Statements This press release contains forward-looking statements, including statements regarding BioCryst’s expectations relating to the use of RESEARCH TRIANGLE PARK, N. has released new real-world evidence demonstrating significant and sustained reductions in Hereditary Angioedema (HAE) attack BioCryst is in the strongest financial position in its history,” said Anthony Doyle, chief financial officer at BioCryst. com Press Release Actions For more information, please visit www. For more information, please visit the Company’s website at www. Forward-Looking Statements This press release contains forward-looking statements, Post-marketing commitments for RAPIVAB are ongoing. (Nasdaq: BCRX) today announced new data on the long-term Get the latest BioCryst Pharmaceuticals, Inc. biocryst. Industry: Pharmaceuticals & Biotechnology Website: https://biocryst. , June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. C. (BCRX) stock news and headlines to help you in your trading and investment decisions. 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. Forward-Looking Statements This This press release contains forward-looking statements, including statements regarding future results, performance or achievements and statements relating to ORLADEYO John Stonehouse, CEO, BioCryst: the earnings press release posted in the press release section of our Investor Relations website at www. . com. (Nasdaq: BCRX) today announced new data on the long-term RESEARCH TRIANGLE PARK, N. gcs-web. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX). –ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P– RESEARCH TRIANGLE PARK, N. (Nasdaq: BCRX) today announced new data on the long-term For more information, please visit www. , Oct. (Nasdaq: BCRX) today announced that it has successfully BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare RESEARCH TRIANGLE PARK, N. (Nasdaq: BCRX) today announced preliminary, unaudited BioCryst Pharmaceuticals, Inc. , Jan. (Nasdaq:BCRX) today reported financial results for the first View the latest Biocryst Pharmaceuticals (BCRX) company-issued press releases. Forward-Looking Statements This press release contains forward-looking statements, This press release contains forward-looking statements, including statements regarding our plans and expectations for our BCX17725 program and other future results, RESEARCH TRIANGLE PARK, N. com or follow us on LinkedIn. For the three months ended September 30, 2024, total This press release contains forward-looking statements, including statements regarding our plans and expectations for our complement program and other future results, Forward-Looking Statements This press release contains forward-looking statements, including statements relating to ORLADEYO safety, performance and effectiveness. RESEARCH TRIANGLE PARK, N. Find the latest press releases and official documents published by BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has successfully Stay up to date with all latest press releases from BioCryst Pharmaceuticals, Inc.